Ascendis Pharma A/S (ASND) vs Insmed (INSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed Insmed (INSM) over the past year, gaining 6.0% versus a loss of 37.9%. Over five years, INSM leads with a +279.3% price change compared with +39.2% for ASND. Insmed is the larger company by market cap ($21.94 billion vs $14.65 billion), about 1.5 times the size.
On valuation, Ascendis Pharma A/S trades at a lower forward P/E (20.7x vs 127.6x for Insmed).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | INSM |
|---|---|---|
| Share price | $222.69 | $100.48 |
| Market cap | $14.65B | $21.94B |
| 1-day change | -2.50% | -1.24% |
| YTD return | +4.43% | -42.27% |
| 1-year return | +5.98% | -37.90% |
| 5-year return | +39.19% | +279.31% |
| P/E ratio (TTM) | 17.06 | — |
| Forward P/E | 20.68 | 127.61 |
| EPS (TTM) | $13.05 | $-4.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $606.42M |
| Revenue growth (YoY) | — | +66.73% |
| Net income (latest FY) | — | $-1.28B |
| Gross margin | — | 79.73% |
| Operating margin | — | -205.59% |
| Net margin | — | -210.54% |
| 52-week high | $282.15 | $212.75 |
| 52-week low | $186.05 | $90.39 |
| Distance from 52-week high | -21.07% | -52.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.34% | +96.80% |
| Average volume | 662.79K | 2.60M |
| Shares outstanding | 65.80M | 218.38M |
| Employees | 1,189 | 1,664 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASND has outperformed INSM by 43.9 percentage points over the past year.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
ASND vs INSM FAQ
Which is bigger, Ascendis Pharma A/S or Insmed?
Insmed (INSM) is larger, with a market capitalization of $21.94B compared with $14.65B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ASND or INSM?
ASND returned +5.98% over the past 12 months, compared with -37.90% for INSM (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and Insmed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.